Physician profile
Jess E Jordan
NPI 1285042259
$1,831.30
in general payments reported to CMS, 2019-2025
22 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $368 · 2023: $394 · 2024: $552 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $555.41 | 2022-2025 | |
| Pfizer INC. | $186.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $140.62 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $134.75 | 2021-2024 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $134.10 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.43 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $95.23 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $77.40 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.79 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.02 | 2021 | |
| Mylan Specialty L.P. | $34.85 | 2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $34.59 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $30.15 | 2021-2022 | |
| Lilly USA, LLC | $28.87 | 2022-2024 | Mounjaro, Zepbound |
| Lundbeck LLC | $21.49 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.87 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.84 | 2024 | Voquezna |
| Eisai INC. | $17.17 | 2021 | |
| Exact Sciences Corporation | $16.28 | 2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $15.49 | 2024 | Thinprep 2000 Processor, Aptima |
| Seqirus USA INC | $11.81 | 2022 | |
| Sunovion Pharmaceuticals INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jess Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.